Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which Anti-Ulcer drug works best for h. pylori? large trial aims to find out

NCT ID NCT07344506

Disease control Sponsor: Dow University of Health Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests three different anti-ulcer medications (Dexlansoprazole, Lansoprazole, and Vonoprazan) combined with two antibiotics (Levofloxacin and Amoxicillin) to see which works best for eradicating H. pylori infection. About 942 adults in Pakistan with H. pylori will take one of the three combinations for 14 days. The main goal is to see which treatment clears the infection most effectively, measured by a breath test four weeks after treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dexlansoprazole, Lansoprazole, or Vonoprazan combined with Levofloxacin and Amoxicillin
What this could lead to
If successful, this could identify the most effective anti-ulcer drug combination for eradicating H. pylori in regions with high antibiotic resistance, potentially reducing stomach cancer risk.
What could go wrong
This is a phase 4 trial in a specific population (Pakistan), so results may not apply elsewhere. Antibiotic resistance could still limit effectiveness, and side effects from the drugs are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 942 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Adult patients of both sexes, presenting to the out-patient departments of the participating healthcare centres, and diagnosed through a UBT to have H.Pylori infection by their physician will be eligible for enrolment in the study, but are currently not receiving any treatment for H.Pylori infection. Exclusion Criteria: 1. Those who will not provide written consent for the study. 2. Patients with severe mental disability, 3. pregnant or lactating women, 4. those who are already on treatment for H.Pylori infection, and 5. those who have received any antibiotic within the last two weeks of enrolling in this study will be excluded. 6. Patients with known previous documented drug allergies for the current regime will be excluded from the trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for H. pylori gastrointestinal disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Helicobacter pylori infectious disease peptic ulcer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

H. pylori gastrointestinal disease H.pylori eradication rate H.pylori infection

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Sindh Institute of Advanced Endoscopy and Gastroenterology (SIAG), DUHS

    RECRUITING

    Karachi, 75600, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.